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Background: Cytotoxic T lymphocytes (CTLs) appear to play 
an important role in the control and prevention of human cy-
tomegalovirus (HCMV) infection. The pp65 antigen is a 
structural protein, which has been defined as a potential tar-
get for effective immunity against HCMV infection. Incorpo-
ration of an 11 amino acid region of the HIV TAT protein 
transduction domain (Tat) into protein facilitates rapid, effi-
cient entry into cells. Methods: To establish a strategy for the 
generation of HCMV-specific CTLs in vitro, recombinant 
truncated N- and C-terminal pp65 protein (pp65 N&C) and 
N- and C-terminal pp65 protein fused with Tat (Tat/pp65 
N&C) was produced in E.coli system. Peripheral blood mono-
nuclear cells were stimulated with dendritic cells (DCs) 
pulsed with pp65 N&C or Tat/pp65 N&C protein and immune 
responses induced was examined using IFN-γ  ELISPOT as-
say, cytotoxicity assay and tetramer staining. Results: DCs 
pulsed with Tat/pp65N&C protein could induce higher T-cell 
responses in vitro compared with pp65N&C. Moreover, the 
DCs pulsed with Tat/pp65 N&C could stimulate both of 
CD8
＋ and CD4
＋ T-cell responses. The T cells induced by 
DCs pulsed with Tat/pp65 N&C showed higher cytotoxicity 
than that of pp65-pulsed DCs against autologous lympho-
blastoid B-cell line (LCL) expressing the HCMV-pp65 
antigen. Conclusion: Our results suggest that DCs pulsed 
with Tat/pp65 N&C protein effectively induced pp65-specific 
CTL in vitro. Tat fusion recombinant protein may be useful for 
the development of adoptive T-cell immunotherapy and 
DC-based vaccines.
[Immune Network 2011;11(3):182-189]
INTRODUCTION
Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus 
that infects 50∼85% of adults. Primary infection with HCMV 
always  leads  to  the virus  persisting for long periods in  the 
host  as  a  latent  infection.  In  immune-compromised  indivi-
duals, HCMV can reactivate and may give rise to a clinical 
illness (1). Several studies show that bone marrow progeni-
tors act as a reservoir of HCMV and transmit the viral genome 
to peripheral blood monocytes, without lytic-gene expression, 
until they leave the circulation and undergo tissue-specific dif-
ferentiation  to  macrophages  (2-6). Infection  and  disease  by 
HCMV  are  major  complications  of  allogeneic  bone  marrow 
transplantations (BMT) (7). HCMV infection commonly occurs 
one  to  three  months  after  transplant  and  may  be  followed 
by  disease  manifestations  approximately  15  days  later  (8).
    Dendritic  cells  (DCs)  are  potent  antigen  presenting  cells 
that bridge innate and adaptive immunity (9). Positioned at 
interfaces  between  organism  and  environment  and  in  lym-
phoid tissues, DC are uniquely suited to recognize and ac-
quire pathogens, process macromolecular antigens into pep-
tides, and initiate immune responses in naive T cells, includ-
ing CD4
＋ Th cells and CD8
＋ cytotoxic lymphocytes (CTL). 
There is considerable interest in harnessing the potent antigen 
presenting  power  of  DC  for  patient  benefit,  and  DC-based 
vaccine  trials  are  ongoing. 
  Expression of HCMV antigens in DCs can be achieved by 
t r a n s f e c t i o n  w i t h  c D N A s  o r  i n f e c t i o n  w i t h  v i r u s e s  e n c o d i n g  Enhanced T Cell Immunity by Tat/pp65 Fusion Protein
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HCMV  antigens  (10).  However,  t h i s  t e c h n i q u e  m a y  h a v e  
some constrains, including gene delivery, prolonged gene ex-
pression,  efficiency,  and  toxicity  (11).  We  have  explored 
transduction of protein antigen into DCs as an alternative to 
genetic modification to elicit CTL in vitro. Bacterial recombi-
nant proteins containing the 11-amino acids HIV TAT protein 
transduction domain (PTD; YGRKKRRQRRR) translocate acr-
oss cell membranes in vivo and in vitro (12,13). The pp65 
(65 kDa lower matrix phosphoprotein) (14), known as glyco-
protein 64 or UL83 of a virion tegument protein and the main 
component  of  the  enveloped  subviral  particle  is  an  im-
munodominant  target  of  CD4
＋ a s  w e l l  a s  C D 8
＋ T  c e l l  r e -
sponses  to  HCMV  (15).
  O u r  r e s u l t s  d e m o n s t r a t e d  t h a t  D C s  p u l s e d  w i t h  N -  a n d  
C-terminal pp65 protein fused with Tat (Tat/pp65 N&C) en-
hanced  induction  of  pp65-specific  CTL  in  vitro. 
MATERIALS AND METHODS
Cloning
The  pp65  cDNA  (UL83;  HCMV  AD169  accession  number 
NC001347)  was  obtained  from  viral  DNA.  Primers  corre-
sponding to the 5’ and 3’ ends of pp65 cDNA were cgaac-
tcgagATGGAGTCGCGCGGTCGCCGT,  with  an  XhoI  restric-
tion  site,  and  gcgcgcggatcc  TCAACCTCGGTGCTT,  with  a 
BamHI restriction site, respectively. The purified HCMV-pp65 
g e ne  w as d ig e st e d w it h  XhoI and BamHI,  and  then  subcl-
oned into a pET15b expression vector (Novagen, Darmstadt, 
Germany) which had been digested with the same restriction 
enzymes. 
  Next, Tat/pp65 gene was annealed to generate a promoter 
encoding  11  amino  acids  (HIV-1  Tat47-57:  YGRKKRRQRRR) 
from the basic domain of HIV-1 Tat. The sequences are, at 
the  5’  and  3’  ends,  respectively:  gcagcatatg-TATGGAAGG-
AAGAAGCGGAGACAGCGACGAAGA-ctcgag-ATGGAGTCGC-
GCGGTCG and gcgcgcggatcc-TCAACCTCGGTGCTT. The Nd-
eI-BamHI - d i g e s t e d  T a t / p p 6 5  g e n e  w a s  l i g a t e d  i n t o  t h e  
NdeI-BamHI-digested  pET15b  vector.
  A minigene was constructed encoding the N-terminal pp65, 
pp65N and C-terminal pp65, pp65C using PCR extension with 
the  following  primers,  at  the  5’ a n d  3 ’  ends,  respectively: 
pp65N  forward  and  reverse  primers  -cgaactcgag-ATGGA-
GTCGCGCGGTCGCCGT,  gctggatcc-TCAATTTTTGGGACACA-
ACAC  and  pp65C  forward  and  reverse  primers  -gaactcga-
g-ATGATAATCAAACCGGGCAAG;  gcgcgcggatcc-TCAACCTC-
GGTGCTT.
  T h e  XhoI-BamHI-digested  pp65N  and  pp65C  gene  was 
cloned into the XhoI-BamHI-digested pET15b or pET15b-Tat 
vectors and finally the DNA sequence can be confirmed by 
automated  DNA  sequencing  (model  373A;  Applied  Biosys-
tems,  Inc.,  CA,  USA).
Production and purification of recombinant protein 
in  E.coli
The  BL21  transformed  with  pp65/pET15b  plasmid  was  in-
oculated  into  2×500  ml  of  LB  broth  containing  100μg/ml 
ampicillin.  After  the  cells  had  grown  until  OD600=0.5∼0.7, 
IPTG  (Isopropyl-β-D-thiogalactoside,  Duchefa  Co.,  Nether-
land) was added to a concentration of 1.5 mM, and the in-
cubation was continued for an additional 3 h. The cells were 
harvested, and a 40 ml binding buffer (8 M Urea, 100 mM 
NaCl, 20 mM HEPES, pH 8) was added and sonicated (model 
VC130;  Sonics  &  Materials,  Inc.,  CT,  USA).
    The  recombinant  pp65  was  purified  under  denaturing 
conditions. To denature pp65, harvested cells were disrupted 
by sonication in a binding buffer containing 8 M urea. After 
centrifugation,  supernatants  containing  pp65  were  immedi-
ately loaded onto a 5 ml Ni
2＋-nitrilotriacetic acid Superflow 
(QIAGEN, Germany) column. The column was washed with 
2  v o l u m e s  o f  b i n d i n g  b u f f e r ,  a n d  8  v o l u m e s  o f  a  w a s h i n g  
buffer (8 M Urea, 100 mM NaCl, 20 mM HEPES, 10 mM imi-
dazole, pH 8). For refolding step, the column was washed 
with  urea  in  each  1  volume  of  refolding  buffer  (0.2% 
Tween20, 0.5% Glycerol, 0.5 M NaCl in PBS, pH 7.4) at de-
creasing concentration (6, 4, 2, 1, 0.5, 0.2, and 0.1 M). The 
fusion protein was eluted with an elution buffer (1 M imida-
zole,  0.1% Tween20, 1%  Glycerol,  0.5 M  NaCl  in PBS, pH 
7.4).  Dialysis  was  then  performed  to  remove  residual  salt. 
    To confirm the presence of purified protein, we performed 
12.5%  sodium  dodecyl  sulfate-polyacrylamide  gel  electrop-
horesis. The protein was visualized either by Coomassie blue 
staining. The protein concentration in fractions was estimated 
by  the  Bradford  procedure  using  bovine  serum  albumin  as 
a  standard  (16). 
Peptide synthesis
The  HLA-A0201  immunodominant  peptide  NLVPMVATV 
(amino acids 495-503 of the HCMV pp65 protein) was synthe-
sized by AnyGen Co. Ltd (Kwangju, Jeonlado, Korea) (17,18).Enhanced T Cell Immunity by Tat/pp65 Fusion Protein
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Induction of monocyte-derived dendritic cells and 
LCL
Six healthy laboratory volunteers were included in this study. 
Consent  forms  and  approval  for  this  study  were  obtained 
from the donors and the Institutional Review Board of The 
Catholic University of Korea, College of Medicine. HLA typing 
was  performed  in  Hematopoietic  Stem  Cell  Bank  (Catholic 
medical  center,  Seoul,  Korea).
    PBMC  were  obtained  from  peripheral  blood  by  standard 
Ficoll-Paque  Plus  (Amersham  Biosciences,  Piscataway,  NJ, 
USA)  separation.  The  adherent  cells  were  isolated  in  RPMI 
1640 complete medium containing 5% FBS at 10
7 cells/well 
in 6-well plates following 2 h incubation at 37
oC. The non-ad-
herent cells were removed and the adherent cells were cul-
tured for 7 days in RPMI 1,640 complete medium containing 
100  ng/ml  GM-CSF  (Endogen,  Woburn,  MA,  USA)  and  500 
U/ml  IL-4  (Genzyme,  Cambridge,  MA,  USA).  Fresh  culture 
medium was added on day 3. After 7 days, non-adherent and 
loosely adherent cells were collected by vigorous pipetting. 
More  than  90%  of  the  cells  showed  DC  phenotype  (MHC 
class  I  molecule
＋,  class  II  molecule
＋,  CD1a
＋,  HLA-DR
＋, 
CD14
−,  CD80
＋)  by  FACS  (data  not  shown). 
  Immature DCs (1∼2×10
6 cells/ml) were treated with re-
combinant  protein  for  2  h  at  37
oC  and  then  recultured  for 
1 day in the presence of 200 units/ml tumor necrosis factor-α 
(TNF-α, R&D System, Inc., Minneapolis, MN, USA), 1μg/ml 
prostaglandin  (PG)-E2  (Sigma-Aldrich  Corp,  St.  Louis,  MO, 
USA)  and  1μg/ml  lipopolysaccharide  (LPS,  Sigma-Aldrich) 
for  maturation.
    LCLs were generated with concentrated supernatants of the 
B95-8 cell line [16]. LCLs were also transduced with pLXSN-
pp65  retrovirus  (LCL/pp65),  to  permit  selection  of  a  pure 
population  for  target  cells  (19).  Both  LCLs  and  LCL/pp65 
were maintained in RPMI 1,640 (GibcoBRL, Grand Island, NY, 
U S A )  s u p p l e m e n t e d  w i t h  1 0 %  f e t a l  b o v i n e  s e r u m  ( F B S ,  
GibcoBRL), 2 mM  L-glutamine (GibcoBRL) and antibiotic anti-
mycotic  mixture  1X;  JBI,  Daegu,  Korea).
Isolation of CD4
＋ and CD8
＋ T cells
CD4
＋ a n d  C D 8
＋  T  cells  were  separated  from  PBMC  using 
MACS  microbeads  and  MidiMACS  positive  selection  column 
type LS according to the manufacturer’s instructions (Miltenyi 
Biotec, Bergisch-Gladbach, Germany). 10
8 PBMC were co-in-
cubated with 50μl of anti-CD4 or anti-CD8 microbeads for 
3 0  m i n  a t  4
oC .  T h e n  c e l l s  w e r e  w a s h e d  w i t h  2  m M  E D T A 
in PBS and applied onto the LS column placed in a magnetic 
filed. Negative cells were passed through the column by rins-
ing with 2 mM EDTA in PBS. Then the column was removed 
from the magnetic filed and positive cells were flushed out. 
The purity of the sorted CD4
＋ or CD8
＋ T cells was measured 
by  FACS  and  was  ＞93%.
IFN-γ ELISPOT assay
The  effector  cells  (PBMCs,  10
6 c e l l s / w e l l )  a n d  D C s  p u l s e d  
with each protein (10
5 cells/well) were mixed and incubated 
4  hr  at  37
oC  in  96-well  U-bottomed  plate  (Falcon,  Becton 
Dickinson Labware, Franklin Lakes, NJ, USA). Control wells 
contained effector cells alone and effector cells in the pres-
ence of mock DCs. After that, a 1 : 50 dilution of effector 
cells  (10
4  cells/well  at  final  volume  of  200μl)  were  added 
t o  a  9 6 - w e l l  a n t i - I F N - γ-coated  ELISPOT  plate  (AutoImmun 
D i a g n o s t i k a  [ A I D ] ,  S t r a s s b e r g ,  G e r m a n y )  i n  d u p l i c a t e s  a f t e r  
blocking with RPMI 1,640 complete medium (10% FBS, 15∼
20  min,  37
oC). 
    The cells were incubated for 18∼20 h at 37
oC in 5% CO2 
and washed six times with washing buffer according to the 
manufacturer’s  instructions.  A  secondary  biotinylated  an-
ti-IFN-γ antibody was then added at 100μl/well for 2.5 hr. 
Plate was washed five times with buffer, and was incubated 
with  streptavidin-horseradish  p e r o x i d a s e  f o r  2  h  a t  r o o m  
temperature.  Plates  were  washed  with  washing  buffer  and 
spot color was developed by adding 3-amino-9-ethylcarbazol 
substrate  diluted  in  acetate  buffer  containing  H2O2.  Plates 
were then washed with distilled water to stop the reaction. 
After drying, images of the wells were acquired using the AID 
E L I S P O T  s o f t w a r e  v e r s i o n  2 . 1  ( A I D ) .  A l l  t h e  e x p e r i m e n t s  
were run at least in duplicate depending on the number of 
cells available. The results are shown as the number of spot 
-forming  cells  (SFC)/10
6 c e l l s .
In vitro CTLs generation 
PBMCs (10
6 cells/ml) were cocultivated with autologous DCs 
pulsed with each protein in 24-well plate (Falcon) in RPMI 
1,640 complete medium containing 10% FBS. DCs were ex-
p o s e d  t o  2 5  G y  o f  γ irradiation  before  use  as  stimulator 
cells. The CTL culture was stimulated weekly following a reg-
imen of decreasing responder: stimulator ratios from 20 : 1 
a t  d a y  0 ,  1 0  :  1  a t  d a y  7  o v e r  p e r i o d  o f  2  w e e k s .
Cytotoxicity assay
Cytotoxic activity of the generated CTL was assessed 1 week 
after the second stimulation by 
51Cr release using autologous Enhanced T Cell Immunity by Tat/pp65 Fusion Protein
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Figure 1. Characterization of recombinant TAT/pp65 fusion protein. (A) Schematic structure of the produced fusion proteins. Proteins used in
this study were pp65, pp65 fused with Tat, N-terminal pp65 (pp65N), C-terminal pp65 (pp65C), N-terminal pp65 with Tat (Tat/pp65N) and 
C-terminal pp65 with Tat (Tat/pp65C). (B) Production of fusion proteins. The protein concentration was estimated by the Bradford procedure
and amount of produced proteins was compared. (C) Confirmation of the purified fusion proteins. The size of purified proteins was examined
using Commassie blue staining after SDS-PAGE; pp65 N (lane 1), Tat/pp65 N (lane 2), and pp65 C (lane 3), Tat/pp65 C (lane 4), pp65 N (lane
5), and Tat/pp65 N (lane 6). 
LCL, LCL/pp65, and allogeneic (HLA-nonmatched) LCL/pp65 
as target. All target cells were labeled with 100μCi 
51Cr in 
0.2 ml RPMI 1,640 complete medium containing 10% FBS at 
37
oC for 1 h. After three washes, the target cells were counted 
and seeded in triplicate in 96-well V-bottomed plates (Falcon) 
at 5×10
3 cells per well. The effector cells were then added 
at  an  indicated  effector-to-target  (E/T)  ratio.  After  cen-
trifugation at 1,200 rpm for 2 min, the plates were incubated 
at 37
oC for 4 hr. The supernatant fluids were harvested and 
51C r  c o n t e n t  w a s  m e a s u r e d .  T h e  p e r c e n t a g e  o f  s p e c i f i c  i n -
corporation was calculated as: [(cpm test-cpm spontaneous)÷ 
(cpm  maximum-cpm  spontaneous)]×100.
Tetramer staining
The  Phycoerythrin  (PE)-labeled  HLA-A2402  tetramers  com-
plexed with the peptide, QYDPVAALF (amino acids 328-336 
of the HCMV pp65 protein) was obtained from Proimmune 
(Oxford,  UK).  Cells  were  incubated  with  a  PE-  labeled 
HLA-A2402/pp65  328-336  tetramer  and  fluorescein  iso-
thiocyanate  (FITC)-labeled  anti-CD8  antibody  (BD  Bioscien-
ces) for 1 h at 4
oC. After incubation, the cells were washed 
and fixed in PBS with 1% paraformaldehyde. Samples were 
analyzed by FACS and at least 50,000 events were collected 
for  each  sample.
RESULTS
Characterization of recombinant TAT/pp65 fusion 
protein
Six  different  recombinant  pp65 proteins  were  produced  for 
this  study:  pp65,  pp65  fused  with  Tat,  N-terminal  pp65 
(pp65N), C-terminal pp65 (pp65C), N-terminal pp65 with Tat 
(Tat/pp65N) and C-terminal pp65 with Tat (Tat/pp65C). The 
structure of each protein was schematically shown in Fig.1A. 
The amount of each protein produced from 1 liter of E.coli. 
was 1.25 mg of pp65, 0.35 mg of Tat/pp65, 1.2 mg of pp65 
N ,  2  m g  o f  T a t / p p 6 5 N ,  1 6  m g  o f  p p 6 5 C ,  a n d  7 . 2  m g  o f  
Tat/pp65C  (Fig.  1B).  The  purified  proteins  were  shown  to Enhanced T Cell Immunity by Tat/pp65 Fusion Protein
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Figure 2. Transduction of protein fused with Tat. (A) Transduction efficacy of protein fused with Tat. DCs were incubated with GFP, or Tat/GFP
for 2 hr, following maturation for 1 day. Then, GFP expression was observed using FACS analysis and was compared between DCs (black line)
and DCs with GFP or Tat/GFP (filled grey) (B) Effect on cell survival after transduction of Tat/pp65 N&C protein. DCs were incubated with 
pp65 N&C or Tat/pp65 N&C protein for 2 h and then stained with annexin 5-PE and 7-AAD. To induce apoptosis, mock DCs were cultured 
with 1μg/ml of actinomycin D (AcD).
h a v e  a  m o l e c u l a r  m a s s  o f  ∼3 4  k D a  f o r  t h e  p p 6 5  N  a n d  
pp65C, ∼35 kDa for the Tat/pp65 N and Tat/pp65C, ∼65 
kDa  for  the  pp65,  and  ∼6 6  k D a  f o r  t h e  T a t / p p 6 5  b y  
Coomassie  blue  staining  (Fig.  1C).  We  used  mixture  of 
Tat-pp65N  and  Tat-pp65C  or  pp65N  and  pp65C  protein  to 
generate  pp65-specific  CTL  because  yield  of  production  of 
full  pp65  protein  was  low.
Transduction efficacy of Tat/pp65 fusion protien into 
DC
To analyze that Tat fusion protein can effectively transfer into 
DCs, DCs were incubated with 0.01, 0.1 and 1 uM of Tat/GFP 
or GFP for 2 h, following maturation for 1 day and GFP ex-
pression in DCs was examined by FACS. When DCs was in-
cubated with Tat/GFP, high expression of GFP protein was 
observed  (Fig.  2A).
    We investigated whether transduction of recombination fu-
s i o n  p r o t e i n  a f f e c t s  d e a t h  o f  DCs  using  Annexin  V/7-AAD 
staining.  Incubation  of  DCs  with  pp65  N&C  and  Tat/pp65 
N&C  protein  did  not  trigger  cell  death  including  apoptosis 
(Fig.  2B).
Enhancement of T cell stimulation by DC pulsed with 
Tat/pp65 fusion protein
To measure the responses of T cells to the recombinant pp65 
protein, PBMCs were stimulated with DCs pulsed with various 
concentration  of  pp65N&C  or  Tat/pp65N&C,  and  the  fre-
quency of IFN-γ producing cells was measured by ELISPOT 
assay. Protein concentration of 0.01 and 0.1μM of Tat/pp65 
N & C  s h o w e d  h i g h e r  f r e q u e n c y  o f  I F N - γ producing  cells 
compared with that of pp65N&C (Fig. 3A). Because protein 
concentration of 0.1μM of Tat-pp65 N&C showed the highest 
frequency of IFN-γ producing cells, 0.1μM of protein was 
used  in  this  study.
    To discriminate CD4
＋ and CD8
＋ T cells responses, CD4
＋ 
and CD8
＋ T cells were incubated with DCs pulsed with pp65 
N&C  and  Tat/pp65  N&C  protein  and  then,  frequency  of 
IFN-γ producing  cells  was  examined  by  ELISPOT  assay. 
CD8
＋ T cells as well as CD4
＋ T cells showed higher fre-
quencies of IFN-γ producing cells when was stimulated with 
DCs pulsed with Tat/pp65 N&C protein compared with pp65 
N&C (Fig. 3B). The pp65-specific CD8
＋ T cells recognized 
Peptide  NV9  (HLA-A2  restricted)  reported  as  CTL  peptides. 
Frequency  of  IFN-γ producing  cells  increased  1.6  fold  in 
CD8  T  cells,  and  0.5  fold  in  CD4  T  cells  in  Tat/pp65N&C 
protein group, indicating that DCs pulsed with Tat/pp65 N&C 
w e r e  m o r e  p o t e n t  i n  s t i m u l a t i n g  C D 8
＋ T  c e l l s  t h a n  D C s  
p u l s e d  w i t h  p p 6 5  N & C .
In vitro generation of pp65-specific CTLs by Tat/pp65 
fusion protein
After  PBMCs  were  stimulated  with  DCs  pulsed  with  pp65 
N & C  o r  T a t / p p 6 5  N & C  p r o t e i n  t h r e e  t i m e s ,  w e  p r o d u c e d  
pp65-specific CTL in vitro and investigated that it could target Enhanced T Cell Immunity by Tat/pp65 Fusion Protein
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Figure 3. Enhancement of T cell
stimulation by DCs pulsed with
Tat/pp65. (A) Stimulation of 
IFN-γ producing cells by vari-
ous concentrations of the re-
combinant pp65 N&C or Tat/ 
pp65 N&C protein. Immature 
DCs were treated with 1, 0.1, 
0.01μM of each protein for 2 
h and then incubated for 1 day
in the presence of TNF-α, PGE2
and LPS for maturation. DCs 
were directly added to 1×10
4
PBMC/well of 96 well plates 
and frequency of IFN-γ pro-
ducing cells was measured by 
the ELISPOT assay. (B) CD4
＋ or
CD8
＋ T cells responses by Tat/
pp65N&C protein. CD4
＋ o r 
CD8
＋ T cells were separated 
from PBMC with MACS micro-
beads and stimulated with DCs 
pulsed with pp65N&C or Tat/ 
pp65N&C. Frequency of IFN-γ
producing cells was measured 
by the ELISPOT assay.
LCL pulsed with pp65 N&C or Tat/pp65 N&C protein using 
IFN-γ ELISPOT assay. T cells generated by DCs pulsed with 
Tat/pp65N&C protein showed higher frequencies IFN-γ pro-
ducing  cells  compared  with  that  of  by  DCs  pulsed  with 
pp65N&C  protein,  when  stimulated  with  LCL  pulsed  with 
pp65  N&C  protein  (Fig.  4A). 
    The cytotoxic activity of the generated CTL was assessed 
by 
51Cr release assay using autologous (HLA-A24, 33) and al-
logeneic  (HLA-A02,  26)  LCL,  LCL/pp65N&C  as  targets  (Fig. 
4B). Cytotoxic activity was significantly higher against autolo-
gous LCL pulsed with pp65N&C in T cells generated with DCs 
pulsed with Tat/pp65 N&C compared with T cells generated 
by DCs pulsed with pp65 N&C (60% versus 43% at E/T ratio 
40 : 1). There was no significant cytotoxic activity against au-
tologous LCL unpulsed with pp65N&C, allogenic (HLA-non-
matched) LCL unpulsed and pulsed with pp65N&C as targets. 
    For  tetramer  assay,  tetrameric  Q9F-HLA-A2402  complex 
was used and the percentage of A24/pp65 tetramer
＋ CD8
＋ 
T-cells  was  analyzed  by  FACS.  A24/pp65  tetramer
＋ C D 8
＋ 
T-cells showed 0.48% in Tat/pp65 N&C and it was twice high-
er percentage than 0.23% in pp65 N&C (Fig. 4C). Together, 
these results suggest that DCs pulsed with Tat/pp65 could ef-
fectively  induce  pp65-specfic  CTLs.
DISCUSSION
The vaccine for treatment of HCMV aims at the activation and 
expansion of antigen-specific CTL through the presentation of 
MHC class I -restricted eptiopes to CD8
＋ T cells. DCs have 
been the potent antigen presenting cell to priming CTL and 
interest has been focused on the way to deliver tumor antigen 
to DCs. Although several epitopes of pp65 for pulsing to DCs 
have been reported until now (20), pp65 epitopes that can 
be recognized by T cells for HCMV immunotherapy remain 
to be limited. Peptide generates antigen-specific immune re-
sponse, but is the short of half time of peptide/MHC com-
plexes and MHC restriction that limits this approach to pa-
tients with specific MHC allotypes. The DCs pulsed with pp65 
protein can induce CTL against various epitopes because pro-
tein antigen contains the undefined antigens including multi-
ple class I-restricted epitopes  a s w el l as  he lp er  pe pt id e.  I n 
addition, antigen protein can be produced on a large scale 
with low cost. Development of system to deliver protein anti-
gen to DCs including Tat fusion protein will improve avail-Enhanced T Cell Immunity by Tat/pp65 Fusion Protein
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Figure 4. In vitro generation of 
pp65-specific CTL by DCs 
pulsed with Tat-pp65 N&C. (A) 
IFN-γ  production by pp65- 
specific CTL. After PBL was 
stimulated with DCs pulsed 
with pp65 N&C or Tat/pp65 
N&C protein three times, the 
generated CTL was simulated 
with LCL pulsed with pp65 
N&C or Tat/pp65 N&C protein.
Then IFN-γ  producing cells 
were analyzed using ELISPOT 
assay. (B) The cytotoxic activity
of the generated CTL. The 
generated CTL were incubated 
with LCL pulsed with pp65 
N&C (dotted lines) and Tat/ 
pp65 N&C (solid lines) labeling
with 
51Cr as target. The amount
of released-
51Cr was measured 
by  γ-counter. (C) pp65-speci-
fic epitopes. HCMVpp65-speci-
fic T cells were generated by 
stimulating PBMC with 0.1μM
pp65 N&C and Tat/pp65 N&C- 
pulsed DCs 1 week after the 
second stimulation (14 days). 
The pp65-specific T cells were 
stained with pp65 HLA-A2402- 
specific tetramer and anti-CD8 
antibody and analyzed by FACS.
The percentage in each FACS 
profile represents tetramer-posi-
tive and CD8
＋ T cells.
ability  of  protein  antigen. 
    To demonstrate whether fusion of pp65 to Tat would en-
hance  the  immunogenic  properties  for  T  cells  stimulation, 
pp65N&C and Tat/pp65N&C protein was produced and com-
pared with immune responses each other. DCs pulsed with 
pp65N&C or Tat/pp65 N&C protein directly stimulated PBMC 
and CD4
＋ and CD8
＋ T cells (Fig. 3B). In addition, pp65-spe-
cific CTL could be generated in vitro with DCs pulsed with 
pp65N&C or Tat/pp65N&C protein (Fig. 4). DCs pulsed with 
Tat pp65N&C protein markedly enhanced the generation of 
pp65-specific CTL in vitro. One of mechanism to improve im-
mune responses of Tat fusion protein may be the increased 
uptake and expression of Tat fusion protein by DCs as shown 
in Fig. 2A, because cation of Tat protein and anion on plasma 
membrane have the binding ability by ionic interaction (21, 
22). 
    Although DCs pulsed with Tat/pp65N&C showed the high-
er frequencies of IFN-γ producing cells compared with DCs 
pulsed with pp65N&C in 0.01 and 0.1 uM concentration, it 
exhibited the decreased frequency in 1 uM of protein concen-
tration (Fig. 3A). High protein concentration of Tat protein 
may be affect on the viability of DCs. Tat/pp65N&C showed 
the higher increase rate in CD8
＋ T cells responses than CD4
＋ 
T cells responses (Fig. 3B), indicating that Tat fusion protein 
is  involved  with  cross  presentation  of  DCs. 
    In conclusion, fusion of Tat protein to pp65 protein in this 
study  enhanced  immunogenicity  of  pp65  antigen  and  DCs 
pulsed  with  Tat-pp65  fusion  protein  induced  effective 
pp65-specific CTL. These results will be helpful for the devel-
opment of adoptive T cell immunotherapy and DC-based im-
munotherapeutic  anti-viral  vaccines  for  the  treatment  of  a 
broad variety of immune-suppressed patients after bone mar-
row  transplantation.Enhanced T Cell Immunity by Tat/pp65 Fusion Protein
Jung-Sun Park, et al.
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